Vedanta Biosciences Closes Extended $45.5 Million Series C Financing
13 May 2019

Vedanta Biosciences Closes Extended $45.5 Million Series C Financing

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse